Boston Scientific Corporation (NYSE:BSX) has been given a consensus rating of “Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $30.00.

Several research firms have recently issued reports on BSX. Zacks Investment Research cut Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. UBS AG restated a “buy” rating and set a $31.00 price objective (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub cut Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Finally, BMO Capital Markets restated a “buy” rating and set a $30.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, June 21st.

Boston Scientific Corporation (NYSE:BSX) traded down 0.14% during midday trading on Friday, reaching $28.93. The company’s stock had a trading volume of 7,680,402 shares. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.40. The firm has a market cap of $39.70 billion, a price-to-earnings ratio of 51.75 and a beta of 1.09. The company has a 50 day moving average price of $27.28 and a 200 day moving average price of $26.52.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the firm earned $0.27 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. On average, equities research analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/16/boston-scientific-corporation-bsx-receives-consensus-recommendation-of-buy-from-brokerages.html.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $26.67, for a total value of $266,700.00. Following the transaction, the executive vice president now directly owns 195,846 shares of the company’s stock, valued at $5,223,212.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John Bradley Sorenson sold 2,100 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $27.15, for a total value of $57,015.00. Following the completion of the transaction, the senior vice president now directly owns 18,880 shares in the company, valued at $512,592. The disclosure for this sale can be found here. Insiders sold 275,257 shares of company stock worth $7,512,394 over the last three months. 0.74% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Boston Scientific Corporation by 7.6% during the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after acquiring an additional 13,105,596 shares during the last quarter. Capital World Investors increased its position in shares of Boston Scientific Corporation by 1.6% during the second quarter. Capital World Investors now owns 101,914,290 shares of the medical equipment provider’s stock worth $2,825,064,000 after acquiring an additional 1,611,442 shares during the last quarter. BlackRock Inc. increased its position in shares of Boston Scientific Corporation by 4.6% during the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after acquiring an additional 4,439,966 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Boston Scientific Corporation by 2.8% during the second quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after acquiring an additional 2,522,556 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Boston Scientific Corporation by 22,491.6% during the second quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after acquiring an additional 38,690,577 shares during the last quarter. 90.52% of the stock is currently owned by institutional investors.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.